Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acut

The Phase 3 GRAPHITE Study Met Its Primary Efficacy Endpoint of Significant and Clinically Meaningful Intestinal aGvHD-Free Survival as Compared to Placebo by Day 180 after Allo-HSCT (pNo New Safety Signals Were Seen with Vedolizumab Compared with Placebo in Patients Who Received Allo-HSCTData Were Presented as A La...

Related Keywords

Osaka ,Japan ,United States ,Japanese ,American ,Bin Chen ,John Cunningham ,Jun Saito ,Cancer Center ,International Blood Marrow Transplant Research ,Hematopoietic Cell Transplant Therapy Program ,Exchange Commission ,European Union ,European Medicines Agency ,Takeda Pharmaceutical Company Limited ,Met Its Primary Efficacy Endpoint ,Clinically Meaningful Intestinal ,Free Survival ,New Safety Signals Were Seen ,Vedolizumab Compared ,Patients Who Received ,Were Presented ,Late Breaking Abstract ,Cellular Therapy Meetings ,American Society ,Cellular Therapy ,International Blood ,Marrow Transplant Research ,Yi Bin Chen ,Hematopoietic Cell Transplant ,Cell Therapy Program ,Mass General Cancer ,Safety Information ,Special Precautions ,Site Reactions ,Product Characteristics ,Prescribing Information ,Medication Guide ,Rare Genetics ,Plasma Derived Therapies ,Annual Report ,Lower Gastrointestinal ,Acute Graft Versus Host Disease ,From Unrelated Donors ,Multicenter Study ,From Pharmacological Prophylaxis ,Intestinal Acute Graft Versus Host Disease ,Annexi Summary ,For Medicinal Products Human ,Pharmacol Exp ,Vedolizumab Patient Exposure ,